

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number

WO 2020/056105 A9

(43) International Publication Date
19 March 2020 (19.03.2020)

(51) International Patent Classification:

C07D 401/12 (2006.01) A61P 25/04 (2006.01)
A61K 31/496 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2019/050771

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

12 September 2019 (12.09.2019)

(48) Date of publication of this corrected version:

09 July 2020 (09.07.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/731,014 13 September 2018 (13.09.2018) US

(15) Information about Correction:

see Notice of 09 July 2020 (09.07.2020)

Previous Correction:

see Notice of 28 May 2020 (28.05.2020)

(71) Applicants: **CELGENE CORPORATION** [US/US]; 86
Morris Avenue, Summit, NJ 07901 (US). **ABIDE THERA-
PEUTICS, INC.** [US/US]; 10835 Road To The Cure, Suite
250, San Diego, CA 92121 (US).

(72) Inventors: **HUANG, Lianfeng**; 556 Morris Avenue, Sum-
mit, NJ 07901 (US). **TSOU, Nancy**; 556 Morris Avenue,
Summit, NJ 07901 (US). **WHITE, Nicole, Suzanne**; 3672
Caminito Cielo Del Mar, San Diego, CA 92130 (US). **XU,
Jun**; Crystal Pharmatech Co., LTD., Suite 101, Bldg B4,
Biobay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou,
215123 (CN). **ZHANG, Qun**; Crystal Pharmatech Co.,
LTD., Suite 101, Bldg B4, Biobay, 218 Xinghu Street,
Suzhou Industrial Park, Suzhou, 215123 (CN).

(74) Agent: **RIEGER, Dale, L.** et al.; Jones Day, 250 Vesey
Street, New York, NY 10281-1047 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: CRYSTALLINE (R)-5-CARBAMOYLPIRIDIN-3-YL-2-METHYL-4-(3-(TRIFLUOROMETHOXY)BENZYL) PIPER-
AZINE-1-CARBOXYLATE, COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: Provided herein are crystalline forms of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate. Pharmaceutical compositions comprising crystalline forms of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate are also disclosed.

WO 2020/056105 A9